All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Aberrant expression of microRNA-155 (miR-155) has been identified in Acute Myeloid Leukemia (AML) and may be related to clinical outcome, however, this still needs to be further characterized. Hu X. L. and Tang A. P. investigated the expression of miR-155 in bone marrow mononuclear cells (BMMNC) of 80 patients with AML and its clinical significance. Their findings were published in the Chinese Association of Pathophysiology’s Journal of Experimental Hematology.
In conclusion, although there is only a small pool of patients, overexpression of miR-155 correlated to poor prognosis in AML. However, no relationship between the levels of miR-155 and clinical features of AML was observed.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox